Back
Brainstorm Cell Therapeutics Stock Predictions
The Tech Disruption Wall Street Isn't Talking About...Yet
This is a paid advertisement for Mode Mobile Regulation A offering. Please read the offering circular and related risks at invest.modemobile.com.
Sell
8
BCLI
Brainstorm Cell Therapeutics
Last Price:
2.23
Seasonality Move:
-7.58%
7 Day Trial
ALL ACCESS PASS
$
7
AI Tech Innovator Poised for Strategic Buyouts Invest Now
Learn MoreBrainstorm Cell Therapeutics Stock Forecast
-
Is Brainstorm Cell Therapeutics Stock Undervalued?
The current Brainstorm Cell Therapeutics [BCLI] share price is $2.34. The Score for BCLI is 8, which is 84% below its historic median score of 50, and infers higher risk than normal. - BCLI is currently trading in the 0-10% percentile range relative to its historical Stock Score levels.
Will Brainstorm Cell Therapeutics Stock Go Up Next Year?
Data Unavailable
Brainstorm Cell Therapeutics Stock Rating
Data Unavailable
Brainstorm Cell Therapeutics Stock Price History
Stock Information
Stock Info
Exchange:
NASDAQ
Country:
United States
Industry:
Biotechnology
Sector:
Health Care
Type:
stock
Website:
brainstorm-cell.com
52-Week Data
52-Week High:
11.89
52-Week Low:
2.01
Prediction Charts
Market Cap:
12.46M
Price in USD:
2.34
Volume:
82.46K
Beta:
-0.06
Technical Analysis
SMA50:
4.27
SMA100:
5.35
SMA200:
5.74
52-Wk Change:
-17.73%
Stock Predictions
-
Is Brainstorm Cell Therapeutics stock public?
Yes, Brainstorm Cell Therapeutics is a publicly traded company. -
What is the Brainstorm Cell Therapeutics stock quote today?
The Brainstorm Cell Therapeutics stock price is 2.34 USD today. -
How to buy Brainstorm Cell Therapeutics stock online?
You can buy Brainstorm Cell Therapeutics shares by opening an account at a top tier brokerage firm, such as TD Ameritrade or tastyworks.
14-Day Historical Data
| Date | Opening | Closing | Minimum | Maximum |
|---|---|---|---|---|
| Sep-17 | 4.05 | 3.93 | 4.11 | 3.90 |
| Sep-18 | 3.92 | 3.57 | 3.97 | 3.57 |
| Sep-19 | 3.60 | 3.60 | 3.84 | 3.54 |
| Sep-20 | 3.64 | 3.64 | 3.74 | 3.53 |
| Sep-23 | 3.68 | 3.56 | 3.86 | 3.56 |
| Sep-24 | 3.60 | 3.62 | 3.96 | 3.60 |
| Sep-25 | 3.65 | 3.66 | 3.75 | 3.60 |
| Sep-26 | 3.66 | 3.82 | 3.86 | 3.62 |
| Sep-27 | 3.60 | 3.34 | 3.72 | 3.30 |
| Sep-30 | 3.34 | 3.45 | 3.78 | 3.18 |
| Oct-1 | 3.37 | 3.28 | 3.71 | 3.14 |
| Oct-2 | 3.26 | 2.66 | 3.32 | 2.50 |
| Oct-3 | 3.26 | 2.64 | 3.32 | 2.50 |
| Oct-4 | 2.37 | 2.34 | 2.54 | 2.22 |
Brainstorm Cell Therapeutics Earnings
Data Unavailable
Brainstorm Cell Therapeutics Forecast Revenue Growth
Data Unavailable
- Analysts estimate an earnings increase this quarter of $0.00 per share, a decrease next quarter of $0.00 per share, an increase this year of $5.55 per share, and an increase next year of $0.08 per share.
* Brainstorm Cell Therapeutics stock forecasts short-term for next days and weeks may differ from long term prediction for next month and year based on timeline differences.